These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16699060)

  • 1. Eosinophilic cellulitis (Wells' syndrome) as a cutaneous reaction to the administration of adalimumab.
    Boura P; Sarantopoulos A; Lefaki I; Skendros P; Papadopoulos P
    Ann Rheum Dis; 2006 Jun; 65(6):839-40. PubMed ID: 16699060
    [No Abstract]   [Full Text] [Related]  

  • 2. Wells' syndrome (eosinophilic cellulitis) secondary to infliximab.
    Tugnet N; Youssef A; Whallett AJ
    Rheumatology (Oxford); 2012 Jan; 51(1):195-6. PubMed ID: 22019801
    [No Abstract]   [Full Text] [Related]  

  • 3. Adalimumab-induced neutropenia in a patient with rheumatoid arthritis.
    Ottaviani S; Cerf-Payrastre I; Kemiche F; Pertuiset E
    Joint Bone Spine; 2009 May; 76(3):312-3. PubMed ID: 19289296
    [No Abstract]   [Full Text] [Related]  

  • 4. Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis.
    Baltà-Cruz S; Alsina-Glbert M; Mozos-Rocafort A; Cervera C; Colomo-Saperas L; Del Río A; Estrach-Panella T
    Acta Derm Venereol; 2009; 89(4):432-3. PubMed ID: 19688168
    [No Abstract]   [Full Text] [Related]  

  • 5. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab).
    Chaves Y; Duarte G; Ben-Said B; Tebib J; Berard F; Nicolas JF
    Dermatology; 2008; 217(4):380. PubMed ID: 18849606
    [No Abstract]   [Full Text] [Related]  

  • 6. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
    Nagashima T; Minota S
    J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
    [No Abstract]   [Full Text] [Related]  

  • 7. Kaposi's disease in a patient on adalimumab for rheumatoid arthritis.
    Bret J; Hernandez J; Aquilina C; Zabraniecki L; Fournie B
    Joint Bone Spine; 2009 Dec; 76(6):721-2. PubMed ID: 19945327
    [No Abstract]   [Full Text] [Related]  

  • 8. Appearance of rheumatoid nodules following anti-tumor necrosis factor alpha treatment with adalimumab for rheumatoid arthritis.
    Scrivo R; Spadaro A; Iagnocco A; Valesini G
    Clin Exp Rheumatol; 2007; 25(1):117. PubMed ID: 17418005
    [No Abstract]   [Full Text] [Related]  

  • 9. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon?
    Stichenwirth M; Riedl E; Pehamberger H; Tappeiner G
    Arch Dermatol; 2008 Jun; 144(6):817-8. PubMed ID: 18559788
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 13. Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab.
    Kurmann PT; Van Linthoudt D; So AK
    Clin Rheumatol; 2009 Jan; 28(1):93-4. PubMed ID: 18818868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Okada SK; Siegel JN
    JAMA; 2006 Nov; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
    [No Abstract]   [Full Text] [Related]  

  • 15. Disseminated histoplasmosis associated with the treatment of rheumatoid arthritis with anticytokine therapy.
    Asrani NS
    Ann Intern Med; 2008 Oct; 149(8):594-5. PubMed ID: 18936512
    [No Abstract]   [Full Text] [Related]  

  • 16. CNS demyelination during anti-tumor necrosis factor alpha therapy.
    Bellesi M; Logullo F; Di Bella P; Provinciali L
    J Neurol; 2006 May; 253(5):668-9. PubMed ID: 16311894
    [No Abstract]   [Full Text] [Related]  

  • 17. Mycobacterium chelonae infection associated with adalimumab therapy.
    Díaz F; Urkijo JC; Mendoza F; de la Viuda JM; Blanco M; Unzurrunzaga A; Ayarza R
    Scand J Rheumatol; 2008; 37(2):159-60. PubMed ID: 18415777
    [No Abstract]   [Full Text] [Related]  

  • 18. Adalimumab-induced asthma.
    Bennett AN; Wong M; Zain A; Panayi G; Kirkham B
    Rheumatology (Oxford); 2005 Sep; 44(9):1199-200. PubMed ID: 15870147
    [No Abstract]   [Full Text] [Related]  

  • 19. Nontuberculous mycobacteria infection and tumor necrosis factor-alpha antagonists.
    Swart RM; van Ingen J; van Soolingen D; Slingerland R; Hendriks WD; den Hollander JG
    Emerg Infect Dis; 2009 Oct; 15(10):1700-1. PubMed ID: 19861085
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C.
    Chen YM; Chen HH; Chen YH; Hsieh TY; Hsieh CW; Hung WT; Lan JL; Chen DY
    Ann Rheum Dis; 2015 Mar; 74(3):626-7. PubMed ID: 25452310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.